Literature DB >> 14708948

Prevalence of human immunodeficiency virus testing in patients with hepatitis B and C infection.

Alysa Krain1, Juan P Wisnivesky, Elizabeth Garland, Thomas McGinn.   

Abstract

OBJECTIVES: To determine the proportion of patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) who are adequately assessed for human immunodeficiency virus (HIV) and to identify variables associated with absence of HIV testing. PATIENTS AND METHODS: We retrospectively reviewed the medical records of patients who had positive serologic test results for reactive HBV and/or HCV between January 1999 and December 1999 and were followed up at a general internal medicine clinic in East Harlem, NY. Data were collected on patient demographics, HIV risk factors, and other variables that might influence the physician's decision to test the patient for HIV. Primary outcomes were HIV tests performed and documented discussions of at-risk HIV behavior.
RESULTS: The HIV tests were performed in 40% (95% confidence interval [CI], 32%-49%) of the 141 patients with reactive HBV and/or HCV serologic test results. Predictors of HIV testing on multivariate logistic regression were age younger than 50 years (odds ratio [OR], 25; 95% CI, 13-3.8), male sex (OR, 1.6; 95% CI, 1.1-2.2), and having an established primary care provider (OR, 2.3; 95% CI, 1.2-3.9). Injection drug use was not significantly associated with HIV testing.
CONCLUSIONS: Although HBV and HCV have clear epidemiological links with HIV, this study shows that a high percentage of these patients are not being tested. Although some of the factors associated with lack of testing were identified, further studies on the barriers to HIV testing are needed to reveal potential approaches to increase rates of HIV testing in this high-risk population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14708948     DOI: 10.4065/79.1.51

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

1.  Update on Hepatitis B and C Coinfection in HIV.

Authors:  Patrick Yachimski; Raymond T Chung
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 2.  Management of chronic hepatitis C.

Authors:  V Lo Re; J R Kostman
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

3.  A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV.

Authors:  Michelle A Lally; Sydney A Montstream-Quas; Sara Tanaka; Sara K Tedeschi; Kathleen M Morrow
Journal:  AIDS Patient Care STDS       Date:  2008-01       Impact factor: 5.078

4.  A comparison of risk factors for HCV-mono-infection, HIV-mono-infection, and HCV/HIV-co-infection in a community setting.

Authors:  Srigayatri Bollepalli; Kathleen Mathieson; Beata Jasiurkowski; Amy Hillier; John Post; Shakil Bhanu; Dean Martin; David H Van Thiel; Abdul Nadir
Journal:  Dig Dis Sci       Date:  2007-06-12       Impact factor: 3.199

5.  The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis.

Authors:  Paola Scognamiglio; Giacomina Chiaradia; Gabriella De Carli; Massimo Giuliani; Claudio Maria Mastroianni; Stefano Aviani Barbacci; Anna Rita Buonomini; Susanna Grisetti; Alessandro Sampaolesi; Angela Corpolongo; Nicoletta Orchi; Vincenzo Puro; Giuseppe Ippolito; Enrico Girardi
Journal:  BMC Infect Dis       Date:  2013-10-10       Impact factor: 3.090

6.  Engagement of African Americans with Rapid HIV Testing and HIV Care.

Authors:  Safiya George Dalmida; Graham J McDougall; George C T Mugoya; Pamela Payne Foster; Makenzie Plyman; Joe Burrage
Journal:  HIV/AIDS Res Treat       Date:  2017-09-22

7.  HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.

Authors:  Ilan Fleisher; Alexander G Geboy; Whitney Nichols; Sameer Desale; Stephen Fernandez; Peter Basch; Dawn A Fishbein
Journal:  PLoS One       Date:  2021-06-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.